Tags : MacroGenics

MacroGenics Plans to Advance the Development of Flotetuzumab for Acute

Shots: Macrogenic plans for the onset of a trial evaluating flotetuzumab + MGA012 to broaden the DOR of flotetuzumab in AML patients. Macrogenic will regain WW rights to develop and commercialize flotetuzumab with the termination of the license agreement with Laboratoires Servier signed on Sept’2012, which will be effective on Jan 15, 2020 MacroGenics has […]Read More

I-Mab Signs an Exclusive License Agreement with MacroGenics to Develop

Shots: MacroGenics to receive $15M up front, up to $135M as development & regulatory milestones and royalties on sales in Greater China. I-Mab to get development & commercialization rights for Enoblituzumab in China, Hong Kong, Macau and Taiwan As per the agreement, I-Mab will lead global clinical studies including its territories. In H2’19, MacroGenics plans […]Read More